FY2028 Earnings Estimate for WVE Issued By Wedbush

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Research analysts at Wedbush issued their FY2028 earnings per share estimates for Wave Life Sciences in a research note issued on Thursday, May 8th. Wedbush analyst Y. Zhong anticipates that the company will earn ($0.88) per share for the year. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share. Wedbush also issued estimates for Wave Life Sciences' FY2029 earnings at ($0.64) EPS.

A number of other research analysts also recently weighed in on the company. Jefferies Financial Group initiated coverage on Wave Life Sciences in a report on Tuesday, February 25th. They issued a "buy" rating and a $26.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Cantor Fitzgerald began coverage on Wave Life Sciences in a research report on Tuesday, April 29th. They set an "overweight" rating and a $10.00 target price for the company. Finally, StockNews.com cut Wave Life Sciences from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.17.

Wave Life Sciences Trading Up 0.5%

WVE stock traded up $0.03 during trading on Monday, reaching $6.33. The stock had a trading volume of 1,306,010 shares, compared to its average volume of 1,285,047. Wave Life Sciences has a 52 week low of $4.25 and a 52 week high of $16.74. The stock's 50 day moving average is $7.42 and its two-hundred day moving average is $10.87. The firm has a market cap of $975.67 million, a PE ratio of -5.70 and a beta of -0.92.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.02). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The firm had revenue of $9.18 million during the quarter, compared to the consensus estimate of $11.65 million. During the same period in the prior year, the company posted ($0.24) EPS.

Hedge Funds Weigh In On Wave Life Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Wave Life Sciences by 9.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 18,673 shares of the company's stock worth $151,000 after purchasing an additional 1,564 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Wave Life Sciences by 16.6% in the 4th quarter. Victory Capital Management Inc. now owns 14,546 shares of the company's stock worth $180,000 after purchasing an additional 2,073 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Wave Life Sciences by 0.9% in the 1st quarter. Bank of New York Mellon Corp now owns 247,251 shares of the company's stock worth $1,998,000 after purchasing an additional 2,278 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after purchasing an additional 2,308 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Wave Life Sciences in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares in the company, valued at $157,443.55. This trade represents a 39.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Paul Bolno sold 169,025 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total value of $1,617,569.25. Following the transaction, the chief executive officer now owns 338,351 shares of the company's stock, valued at $3,238,019.07. This represents a 33.31% decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.